Follow the 지에프씨생명과학 share price and the full management transaction log of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 지에프씨생명과학 has recorded 41 insider filings. Market capitalisation: €29.8bn. The latest transaction was disclosed on 16 July 2026 (Purchase). Among the most active insiders: 강희철. Every trade is free.
35
Insider Decl.
n/a
Thresholds
€2m
21 ops.
Buy Volume
n/a
4 ops.
Sell Volume
5Σ signal
Buys €2mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,669 of 28,017 companies
35.5
score / 100
Value
26
Quality
45
FCF yld-20%
Earn yld1.8%
EV/EBITDA18.5x
ROE4.1%
Gross mgn48%
Net mgn3.1%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.